Latest Hotspot

Mabwell Discloses Initial Patient Treatment in Phase Ib/II Study for Nectin-4 Focused ADC coupled with PD-1 Inhibitor

10 October 2023
3 min read

Mabwell, a pioneer in the biopharmaceutical sector with a comprehensive industry chain, declared the administration of the first patient dosage in a Phase Ib/II study. This trial involves their novel Nectin-4 targeting ADC (9MW2821), used together with a PD-1 inhibitor to manage locally advanced or metastatic urothelial carcinoma.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

This study is designed to assess the safety, tolerability, initial efficacy, and pharmacokinetic characteristics of 9MW2821 when used with the PD-1 inhibitor in patients struggling with advanced local or metastatic urothelial carcinoma.

9MW2821 is a novel Nectin-4 targeting ADC developed by world-class ADC development platform and automated high-throughput antibody discovery platform of Mabwell. It achieves site-determined modifications of the antibody using trademarked conjugate technology linkers and an enhanced ADC conjugation method. 9MW2821 can attach specifically to Nectin-4 on the cellular membrane surface, internalize and spring a cytotoxic drug, leading to the programmed death of cancer cells.

9MW2821 brings the benefits of a uniform composition, greater purity, and is adaptable for industrial enlargement. Initial results point towards solid tumours yielding positive therapeutic results and having a sound safety profile at the recommended phase II dosage.

Mabwell is currently encouraging enrollment from multiple cohorts for urothelial carcinoma, cholangiocarcinoma, prostate cancer, HER-2 negative breast cancer, and non-small cell lung cancer. The R&D developments of 9MW2821 are leading in China and are ranked second globally. 9MW2821 leads in garnering initial clinical data in cervical cancer among similar targeted treatments internationally. 

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of October 8, 2023, there are 4 investigational drugs for the Tubulin and nectin-4 target, including 18 indications,11 R&D institutions involved, with related clinical trials reaching 50and as many as 123 patents.

9MW2821 is a Monoclonal antibody and Antibody drug conjugate that targets Tubulin and nectin-4. The drug shows potential in treating neoplasms, including Transitional Cell Carcinoma, Solid Tumors, and Advanced Malignant Solid Neoplasm. Further research and clinical trials will be necessary to determine its safety and efficacy in treating these conditions.

Analysis on the Clinical Research Progress of Myostatin inhibitors
Analysis on the Clinical Research Progress of Myostatin inhibitors
10 October 2023
Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletalmuscle, was first described in 1997.
Read →
ImmunoGenesis administers first patient in the Phase 1a/1b clinical study of IMGS-001 for advanced solid tumors
Latest Hotspot
3 min read
ImmunoGenesis administers first patient in the Phase 1a/1b clinical study of IMGS-001 for advanced solid tumors
10 October 2023
ImmunoGenesis announced the first patient treatment in their Phase 1a/1b trial using IMGS-001 at The University of Texas MD Anderson Cancer Center.
Read →
Analysis on the Research Progress of Chk1 inhibitor
Analysis on the Research Progress of Chk1 inhibitor
10 October 2023
Chk1, also known as checkpoint kinase 1, is a crucial protein kinase involved in the regulation of cell cycle progression and DNA damage response in the human body.
Read →
The FDA grants Merck accelerated consideration for their new BLA for the Activin Signaling Inhibitor, Sotatercept
Latest Hotspot
3 min read
The FDA grants Merck accelerated consideration for their new BLA for the Activin Signaling Inhibitor, Sotatercept
10 October 2023
Merck has declared that a fresh BLA for sotatercept has been approved for accelerated assessment by the U.S. FDA.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.